These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Subgroups of patients with very large gastrointestinal stromal tumors with distinct prognoses: a multicenter study.
    Author: Wada N, Kurokawa Y, Nishida T, Takahashi T, Toyokawa T, Kusanagi H, Hirota S, Tsujinaka T, Mori M, Doki Y.
    Journal: J Surg Oncol; 2014 Feb; 109(2):67-70. PubMed ID: 24155204.
    Abstract:
    BACKGROUND AND OBJECTIVES: Any gastrointestinal stromal tumors (GISTs) larger than 10 cm are classified as "high risk" according to the modified National Institutes of Health consensus criteria. We conducted a multicenter study to identify a subgroup with moderate prognosis even within the "high-risk" group. METHODS: We retrospectively collected data on 107 patients with tumors ≥10 cm from a multicenter database of GIST patients. Patients with macroscopic residual lesions or tumor rupture were excluded. The relationship between recurrence-free survival (RFS) and clinicopathological factors was analyzed. RESULTS: The median tumor size and mitotic count were 12.5 cm and 8/50 HPF. The RFS rate was 58.5% at 3 years, 52.1% at 5 years. Only mitotic count was an independent prognostic factor of RFS in the multivariate analysis (P = 0.001). The hazard ratio for recurrence in the subgroup with mitotic count >5/50 HPF was 2.91 (95% confidence interval, 1.53 to 5.56). The subgroup with mitotic count ≤5/50 HPF showed significantly better RFS than the mitotic count >5/50 HPF subgroup (P < 0.001). CONCLUSIONS: Mitotic count is closely associated with outcome in patients with large GISTs. This suggests that the subset of large GISTs with low mitotic counts may be considered as "intermediate-risk" lesions.
    [Abstract] [Full Text] [Related] [New Search]